2008). The mechanism could be downregulation of the Akt-dependent canonical Wnt signaling pathway and p27kip pathway. Wogonin could also act as CDK (cyclin-dependent kinase) inhibitors to potentiate the activities of anti-tumor drugs, such as the Bcl-2 (B-cell lymphoma 2) family inhibitor ABT-263. The combination of wogonin (50 mg/kg for 10 d, i.p.)and ABT-263 remarkably promoted tumor regression in human T-cell leukemia xenografted mice, but wogonin did not exhibit significant effects when used alone (Polier et al. 2015). The gene discussed is BCL2; the disease is neoplasm.